Ohr Gained US and European Patients Entitled, Preparation of a Therapeutic Composition

Ohr Pharmaceutical has gained US and European patients entitled, preparation of a therapeutic composition.

The patents cover claims related to the chemical structures, sequences of the peptide constituents and method of manufacture of OHR/AVR118.

Ohr Pharmaceutical CEO Irach Taraporewala said the patents strengthen the company's OHR/AVR118 cancer cachexia program currently being investigated in a Phase II clinical trial.

"OHR/AVR118 has the potential to greatly benefit advanced cancer patients suffering from the debilitating effects of cachexia," Taraporewala added.

"Stronger, more stable patients have a much better chance of tolerating the intense chemotherapies and radiation therapies involved in treating late stages of cancer."

Ohr is a pharmaceutical company focused on the clinical development of new drugs for underserved therapeutic needs in growing markets.